Rheumatoid Arthritis [2017]: Bulletin #2

Rheumatoid Arthritis [2017]: Bulletin #2


Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of rheumatoid arthritis (RA). Topics covered in this update bulletin include expert opinions on; Johnson & Johnson announcing the FDA’s rejection of Plivensia (sirukumab); Can-Fite concluding its cardiodynamic trial for piclidenoson (CF 101) and being given approval to begin a global Phase III trial in patients with RA; and AbbVie announcing data from the Phase III SELECT-NEXT trial for upadacitinib in patients with RA.

Reasons to Purchase

Business Questions:

How do KOLs regard Plivensia and what are its chances of coming to market?

How would Plivensia fare against other IL-6 inhibitors for RA?

According to KOLs, what lies ahead for IL-6 inhibitors as a class?

How do KOLs view the piclidenoson ACRobat study versus methotrexate?

If approved, how would piclidenoson be prescribed?

Does upadacitinib differentiate itself from other JAK inhibitors?

Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook